Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1)
- The report reviews Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Overview 8
Therapeutics Development 9
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Products under Development by Stage of Development 9
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Products under Development by Therapy Area 10
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Products under Development by Indication 11
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Products under Development by Companies 15
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Products under Development by Universities/Institutes 19
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 26
AbbVie Inc. 26
Amgen Inc. 27
Astex Pharmaceuticals, Inc. 28
CASI Pharmaceuticals Inc. 29
Merck & Co., Inc. 30
Millennium Pharmaceuticals, Inc. 31
Sanofi 32
Sareum Holdings Plc 33
Sigma-Tau S.p.A. 34
Taiho Pharmaceutical Co., Ltd. 35
Vertex Pharmaceuticals Incorporated 36
Vichem Chemie Research Ltd. 37
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Drug Profiles 38
alisertib - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AMG-900 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
AT-9283 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
danusertib - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ENMD-2076 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ilorasertib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MK-8745 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SAR-156497 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SAR-3 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
SAR-4 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Inhibit Aurora A Kinase for Oncology - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ST-5589 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
TAS-119 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
VE-465 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Dormant Projects 68
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Discontinued Products 77
Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Featured News & Press Releases 79
Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma 79
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 79
Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference 79
Nov 05, 2015: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting 80
Nov 04, 2015: CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma 81
Oct 14, 2015: CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma 82
Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors 82
Jun 04, 2015: CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar Carcinoma 82
May 12, 2015: Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma 83
Mar 30, 2015: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 83
Mar 25, 2015: CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 84
Feb 09, 2015: CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For Fibrolamellar Carcinoma 84
Dec 17, 2014: CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 85
Nov 12, 2014: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma 86
Jul 21, 2014: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables

Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Assessment by Monotherapy/Combination Products, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 25
Pipeline by AbbVie Inc., H1 2016 26
Pipeline by Amgen Inc., H1 2016 27
Pipeline by Astex Pharmaceuticals, Inc., H1 2016 28
Pipeline by CASI Pharmaceuticals Inc., H1 2016 29
Pipeline by Merck & Co., Inc., H1 2016 30
Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 31
Pipeline by Sanofi, H1 2016 32
Pipeline by Sareum Holdings Plc, H1 2016 33
Pipeline by Sigma-Tau S.p.A., H1 2016 34
Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 35
Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 36
Pipeline by Vichem Chemie Research Ltd., H1 2016 37
Dormant Projects, H1 2016 68
Dormant Projects (Contd..1), H1 2016 69
Dormant Projects (Contd..2), H1 2016 70
Dormant Projects (Contd..3), H1 2016 71
Dormant Projects (Contd..4), H1 2016 72
Dormant Projects (Contd..5), H1 2016 73
Dormant Projects (Contd..6), H1 2016 74
Dormant Projects (Contd..7), H1 2016 75
Dormant Projects (Contd..8), H1 2016 76
Discontinued Products, H1 2016 77
Discontinued Products (Contd..1), H1 2016 78